CA3210658A1 - Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis - Google Patents

Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis Download PDF

Info

Publication number
CA3210658A1
CA3210658A1 CA3210658A CA3210658A CA3210658A1 CA 3210658 A1 CA3210658 A1 CA 3210658A1 CA 3210658 A CA3210658 A CA 3210658A CA 3210658 A CA3210658 A CA 3210658A CA 3210658 A1 CA3210658 A1 CA 3210658A1
Authority
CA
Canada
Prior art keywords
water
ch3cn
nh4hco3
mmol
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210658A
Other languages
English (en)
French (fr)
Inventor
Richard T. Beresis
John Cijiang He
Kyung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
US Department of Veterans Affairs
Original Assignee
Icahn School of Medicine at Mount Sinai
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, US Department of Veterans Affairs filed Critical Icahn School of Medicine at Mount Sinai
Publication of CA3210658A1 publication Critical patent/CA3210658A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA3210658A 2021-02-10 2022-02-09 Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis Pending CA3210658A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147859P 2021-02-10 2021-02-10
US63/147,859 2021-02-10
PCT/US2022/015767 WO2022173795A1 (en) 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS

Publications (1)

Publication Number Publication Date
CA3210658A1 true CA3210658A1 (en) 2022-08-18

Family

ID=82837244

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3210658A Pending CA3210658A1 (en) 2021-02-10 2022-02-09 Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis

Country Status (9)

Country Link
US (1) US20250179084A1 (https=)
EP (1) EP4291183B1 (https=)
JP (1) JP2024506387A (https=)
KR (1) KR20230154194A (https=)
CN (1) CN117479934A (https=)
AU (1) AU2022221336A1 (https=)
CA (1) CA3210658A1 (https=)
MX (1) MX2023009323A (https=)
WO (1) WO2022173795A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240051965A1 (en) * 2022-08-05 2024-02-15 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2069335T3 (pl) * 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
PE20091339A1 (es) * 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2210890A1 (en) * 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
ES2907624T3 (es) * 2017-01-06 2022-04-25 Icahn School Med Mount Sinai Inhibidores de oxadiazol de HIPK2 para el tratamiento de la fibrosis renal
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法

Also Published As

Publication number Publication date
MX2023009323A (es) 2023-12-14
WO2022173795A1 (en) 2022-08-18
US20250179084A1 (en) 2025-06-05
CN117479934A (zh) 2024-01-30
JP2024506387A (ja) 2024-02-13
EP4291183A1 (en) 2023-12-20
AU2022221336A1 (en) 2023-08-24
EP4291183B1 (en) 2026-04-08
KR20230154194A (ko) 2023-11-07
EP4291183A4 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
CA2237221C (en) Protein kinase c inhibitor
KR102485620B1 (ko) Acc 억제제 및 그의 고체 형태를 제조하는 방법
JP2025527298A (ja) 三環式化合物及びその医薬用途
CN115867556B (zh) Lpa受体拮抗剂及其用途
AU2019326368B2 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
JP7187575B2 (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
BR112014030577B1 (pt) Dihidronaftiridinas e compostos relacionados, bem como composições farmacêuticas compreendendo os mesmos
KR20130002317A (ko) Ｎａｄｐｈ 옥시다아제 억제제인 피라졸로 피페리딘 유도체
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
WO2015172732A1 (zh) 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
HUE024989T2 (en) Azaindole derivatives as ABI and SRC protein kinase inhibitors
CN116120296A (zh) 一种多环化合物、包含其的药物组合物、其制备方法及其用途
JP2018138609A (ja) ナフチリジンジオン誘導体
EP4074699A1 (en) Compound as cyclin-dependent kinase 9 inhibitor and use thereof
US6268375B1 (en) 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
JP2025156455A (ja) チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤
EP4291183B1 (en) Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis
JP2017516829A (ja) ピリドピリミジンジオン誘導体
KR20240154590A (ko) Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물
CN116655557A (zh) 苯并噻唑类化合物、其制备方法及应用
AU2020410900B2 (en) Compound used as RET kinase inhibitor and application thereof
AU2018379438B2 (en) Imidazopyridine derivatives and the use thereof as medicament
CA3089666A1 (en) Ghrelin o-acyltransferase inhibitors
CN117050134A (zh) 酰胺化合物的合成及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260130

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260209

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH

Effective date: 20260209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260211

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260220

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260220

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260224

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D161 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PPH RETAINED AFTER REVIEW

Effective date: 20260224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260323

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260401

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260401